Webinar | Why 95% of AI Projects Stall – and How Agentic AI Changes the Game
The period immediately following Data Base Lock (DBL) is often the most stressful window in a clinical trial. While the “hard work” of data collection
In the high-stakes environment of clinical development, the burden of documentation has reached a tipping point. Medical writers and clinical teams are increasingly sidelined by
According to the Tufts Center for the Study of Drug Development, the average clinical trial can take 7–10 years from discovery to approval, and delays
If you read Part 1 of this series, you’ve already seen how Interactive Review Listings (IRLs) simplify and speed up the core data review process.
How AI evolved from pattern recognition to autonomous reasoning, and why pharmaceutical leaders need to understand the difference The $2.23 Billion Question Developing a single
Let’s take a minute to think about what it really takes to bring a new medicine to patients- it’s a massive, critical effort, but too
Clinical data review has always been one of those parts of a trial that takes more time than anyone expects. An industry report by NIH
If your company is experimenting with AI, here’s a statistic worth pausing on. Recent MIT research says “95% of AI initiatives fail to show real
The pharmaceutical industry has cracked some of its toughest challenges, from shortening trial timelines to improving patient recruitment and building sophisticated data platforms. Yet one
Get our perspectives on AL/ML in the life sciences industry directly to your inbox.
